糖尿病合并无症状左室收缩功能障碍患者新发心力衰竭风险
在SOLVD-P预防研究中,4223例无症状左室收缩功能障碍患者中647例(15%)基线合并糖尿病;中位随访36个月,糖尿病患者新发心衰风险升高(HR 1.53,95%CI 1.32-1.78),心衰住院风险亦升高(HR 2.04,95%CI 1.65-2.52);依那普利疗效不受糖尿病状态影响。
要点
- 无症状左室收缩功能障碍患者中,糖尿病与新发心衰风险升高相关(HR 1.53)。
- 糖尿病亦与心衰住院风险升高相关(HR 2.04)。
- 依那普利对结局的效应未因糖尿病状态而改变。
核心结论
- 在无症状左室收缩功能障碍患者中,糖尿病与进展为新发心衰的风险升高相关。
- 新发心衰与死亡风险升高相关,且此关联不受糖尿病状态影响。
研究设计与样本
- 研究为左室功能障碍研究预防臂(SOLVD-P)的分析,纳入4223例合格参与者,其中647例(15%)基线合并糖尿病。
- 采用累积发病率曲线和Cox回归模型分析,校正年龄、性别、随机治疗、心衰严重程度及合并症等预后因素。
主要发现
- 中位随访36个月,无糖尿病患者3576例中861例(24%)发生心衰,糖尿病患者647例中214例(33%)发生心衰。
- 未校正分析中,糖尿病患者新发心衰风险升高(HR 1.53,95%CI 1.32-1.78;P<0.001)。
- 糖尿病患者心衰住院风险升高(HR 2.04,95%CI 1.65-2.52;P<0.0001)。
- 糖尿病患者心衰发生或心血管死亡复合结局风险升高(HR 1.48,95%CI 1.30-1.69;P<0.001)。
- 依那普利对结局的效应未因糖尿病状态而改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although diabetes is well known to be common in prevalent heart failure (HF) and portends a poor prognosis, the role of diabetes in the development of incident HF is less well understood. We studied the role of diabetes in the transition from asymptomatic left ventricular systolic dysfunction (ALVSD) to overt HF in the prevention arm of the Studies of Left Ventricular Dysfunction (SOLVD-P). RESEARCH DESIGN AND METHODS: We examined the development of symptomatic HF, HF hospitalization, and cardiovascular death according to diabetes status at baseline in patients in SOLVD-P. These outcomes were analyzed by using cumulative incidence curves and Cox regression models adjusted for age, sex, and other prognostic factors, including randomized treatment, HF severity, and comorbidity. RESULTS: Of the 4,223 eligible participants, 647 (15%) had diabetes at baseline. Patients with diabetes were older and had a higher average weight, systolic blood pressure, and heart rate. During the median follow-up of 36 months, 861 of the 3,576 patients without diabetes (24%) developed HF compared with 214 of the 647 patients with diabetes (33%). In unadjusted analyses, patients with diabetes had a higher risk of development of HF (hazard ratio 1.53 [95% CI 1.32-1.78]; P < 0.001), HF hospitalization (2.04 [1.65-2.52]; P < 0.0001), and the composite outcome of development of HF or cardiovascular death (1.48 [1.30-1.69]; P < 0.001). The effect of enalapril on outcomes was not modified by diabetes status. CONCLUSIONS: In patients with ALVSD, diabetes is associated with an increased risk of developing HF. Development of HF is associated with an increased risk of death irrespective of diabetes status.
引用
- Rørth R, Jhund PS, Mogensen UM, et al. Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care. 2018. PMID: 29626073. doi:10.2337/dc17-2583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。